Skip to main navigation

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

October 5, 2020

Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Additional Formats

PDF Version

September 2, 2020

Kodiak Sciences to Present at Upcoming Conferences

Additional Formats

PDF Version

August 10, 2020

Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

July 27, 2020

Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases

Additional Formats

PDF Version

July 16, 2020

Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress

Additional Formats

PDF Version

July 10, 2020

Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting

Additional Formats

PDF Version

July 7, 2020

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar

Additional Formats

PDF Version

May 28, 2020

Kodiak Sciences to Present at Upcoming Conferences

Additional Formats

PDF Version

May 11, 2020

Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference

Additional Formats

PDF Version

May 11, 2020

Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 31 - 40 of 88

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2022 Kodiak Sciences Inc.